Affiliations 

  • 1 Pharmacy Department, Hospital Pulau Pinang, Ministry of Health Malaysia, George Town, Malaysia
  • 2 Pharmacy Department, Northeast District Health Office, Penang, Ministry of Health Malaysia, George Town, Malaysia
  • 3 Pharmacy Department, Hospital Balik Pulau, Ministry of Health Malaysia, Balik Pulau, Malaysia
  • 4 Clinical Research Centre, Hospital Raja Permaisuri Bainun, Ministry of Health Malaysia, Ipoh, Malaysia. davidcct.crc@gmail.com
  • 5 Pharmacy Department, Hospital Bukit Mertajam, Ministry of Health Malaysia, Bukit Mertajam, Malaysia
  • 6 Pharmacy Department, Hospital Sungai Bakap, Ministry of Health Malaysia, Sungai Jawi, Malaysia
  • 7 Pharmacy Department, Hospital Seberang Jaya, Ministry of Health Malaysia, Perai, Malaysia
  • 8 Pharmacy Department, Southwest District Health Office, Penang, Ministry of Health Malaysia, Balik Pulau, Malaysia
  • 9 Pharmacy Department, North District Health Office, Seberang Perai, Ministry of Health Malaysia, Kepala Batas, Malaysia
  • 10 Pharmacy Department, Center District Health Office, Seberang Perai, Ministry of Health Malaysia, Bukit Mertajam, Malaysia
  • 11 Pharmacy Department, South District Health Office, Seberang Perai, Ministry of Health Malaysia, Nibong Tebal, Malaysia
  • 12 Medical Department, Hospital Pulau Pinang, Ministry of Health Malaysia, George Town, Malaysia
  • 13 Penang Pharmaceutical Services Division, Ministry of Health Malaysia, George Town, Malaysia
J Pharm Policy Pract, 2023 Jul 05;16(1):83.
PMID: 37408067 DOI: 10.1186/s40545-023-00583-8

Abstract

BACKGROUND: Pharmacist's involvement in optimizing medication adherence among diabetic patients has been implemented for over a decade. Diabetes Medication Therapy Adherence Clinic (DMTAC) was set up to educate diabetic patients, monitor treatment outcomes, and manage drug-related problems. While evidence shows that pharmacist-led DMTAC was effective in reducing HbA1c, there was limited data regarding the impact of different intervention types and default to follow-up on glycemic control.

AIM: To assess the impact DMTAC on glycemic control and the difference in glycemic control between hospital and health clinic settings as well as defaulter and non-defaulter. In addition, the impact of pharmacist's interventions, DMTAC follow-up frequencies, and duration of diabetes on glycemic control were also determined.

METHODS: A retrospective study was conducted among diabetes patients under DMTAC care between January 2019 and June 2020 in five hospitals and 23 primary health clinics. Patients' demographics data, treatment regimens, frequencies of DMTAC visits, defaulter (absent from DMTAC visits) and types of pharmacists' intervention were retrieved from patients' medical records and electronic database. HbA1c was collected at baseline, 4-6 months (post-1), and 8-12 months (post-2).

RESULTS: We included 956 patients, of which 60% were females with a median age of 58.0 (IQR: 5.0) years. Overall, the HbA1c reduced significantly from baseline (median: 10.2, IQR: 3.0) to post-1 (median: 8.8, IQR: 2.7) and post-2 (median: 8.3, IQR: 2.6%) (p 

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.